A biotech funding round is financing clinical studies to advance a brain‑penetrant SARM1 inhibitor approach for ALS patients.
Key Takeaways
- Company closed a $73.8 million Series B financing led by The Column Group
- Financing will fund clinical proof-of-biology studies and first patient was dosed in NB-4746
- NB-4746 prevented axon degeneration preclinically and reached target plasma and CSF exposure